Jeffrey Wallin, Ph.D. of Genentech presents “Opening the Floodgates to T Cells Biomarkers for the Combination of Bevacizumab and Atezolizumab in RCC” at the 14th International Kidney Cancer Symposium.
Advertisement
[the_ad id="32629"]
Opening the Floodgates to T Cells – Biomarkers for the Combination of Bevacizumab and Atezolizumab in RCC
By Editor